Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Biological: LVGN6051 Monoclonal Antibody InjectionBiological: toripalimab Injection
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Lyvgen Biopharma Holdings Limited
- Target Recruit Count
- 64
- Registration Number
- NCT06378177
- Locations
- 🇨🇳
Anhui Cancer Hospital, Hefei, Anhui, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
A Study of LVGN6051 Combined with Anlotinib in Patient with Soft Tissue Sarcoma
- Conditions
- Soft Tissue Sarcoma
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Lyvgen Biopharma Holdings Limited
- Target Recruit Count
- 65
- Registration Number
- NCT05301764
- Locations
- 🇨🇳
Henan cancer hospital, Zhenzhou, Henan, China
🇨🇳Hunan Cancer Hospital, Changsha, Hu Nan, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Study of LVGN7409 (CD40 Agonist Antibody) in Locally Advanced, Metastatic or Recurrent/Refractory Malignancy
- Conditions
- Cancer
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Lyvgen Biopharma Holdings Limited
- Target Recruit Count
- 33
- Registration Number
- NCT05152212
- Locations
- 🇨🇳
Center Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Study of LVGN6051 (CD137 Agonist Antibody) in Advanced or Metastatic Malignancy
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Lyvgen Biopharma Holdings Limited
- Target Recruit Count
- 18
- Registration Number
- NCT04694781
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
🇨🇳Shanghai Chest Hospital, Shanghai, China
Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Lyvgen Biopharma Holdings Limited
- Target Recruit Count
- 126
- Registration Number
- NCT04635995
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
- Prev
- 1
- 2
- Next